MONTREAL , Aug. 1, 2024 /PRNewswire/ — Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson’s disease and AAT-deficient lung and liver disease, announced today its participation in the Barclays Biotech: 1×1 Private Company Symposium on Wednesday, August 7 , 2024.
This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors.
About Congruence Therapeutics
Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.
For more information, please visit www.congruencetx.com .
Company Contact
Charles Grubsztajn
Chief Operating Officer
cgrubsztajn@congruencetx.com
Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243
View original content to download multimedia:https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1×1-private-company-symposium-302212895.html
SOURCE Congruence Therapeutics
